Results 61 to 70 of about 2,820 (114)

Additional file 1 of Effectiveness and safety of intravenous golimumab with and without concomitant methotrexate in patients with rheumatoid arthritis in the prospective, noninterventional AWARE study

, 2023
Additional file 1. Figure S1. Mean changes from baseline at Month 6 and Month 12 in CDAI score biologic-naïve and biologic-experienced patients receiving IV golimumab with and without methotrexate (observed data). Figure S2. Proportions of biologic-naïve patients in remission (CDAI ≤ 2.8) and with low disease activity (CDAI > 2.8 to ≤ 10), moderate ...
Broadwell, Aaron, Schechtman, Joy, Conaway, Douglas, Kivitz, Alan, Shiff, Natalie J., Black, Shawn, Xu, Stephen, Langholff, Wayne, Schwartzman, Sergio, Curtis, Jeffrey R.   +9 more
openaire   +1 more source

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study

The Journal of Rheumatology
Objective To report pharmacokinetics (PK), immunogenicity, clinical effect, and safety of intravenous (IV) golimumab in children with active polyarticular-course juvenile idiopathic arthritis (pcJIA) who participated in A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in ...
Brunner H. I., Pacheco-Tena C., Louw I., Vega-Cornejo G., Alexeeva E., Appenzeller S., Chasnyk V., Griffin T., Suarez C. N., Knupp-Oliveira S., Zeft A., Aviel Y. B., De Ranieri D., Gottlieb B. S., Levy D. M., Rabinovich C. E., Silva C. A., Spivakovsky Y., Uziel Y., Ringold S., Xu X. L., Leu J. H., Lam E., Wang Y., Lovell D. J., Martini A., Ruperto N., Borzutzky A., Cuttica R., Grebenkina L., Inman C. J., Keltsev V., Kingsbury D. J., Malievskiy V., Pedrosa Fernandes T. A., del Rocio Maldonado Velazquez M., Schmeling H., Scott C., Spindler A., Terreri M. T., Viola D. O., Xavier R. M.   +41 more
openaire   +3 more sources

Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. [PDF]

Paediatr Drugs, 2022
Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, Nelson RM, Zhou H, Xu Z.   +8 more
europepmc   +1 more source

Intravenous golimumab effective for PsA [PDF]

Nature Reviews Rheumatology, 2017
openaire   +1 more source

GO-FURTHER with intravenous golimumab for active RA [PDF]

Nature Reviews Rheumatology, 2012
openaire   +1 more source

POS0902 EFFICACY AND SAFETY OF INTRAVENOUS GOLIMUMAB IN ANKYLOSING SPONDYLITIS PATIENTS WITH EARLY VS LATE DISEASE THROUGH WEEK 52 OF GO-ALIVE STUDY [PDF]

Annals of the Rheumatic Diseases, 2021
A. Deodhar, S. Kafka, E.C. Hsia, K.H. Lo, L. Kim, S. Xu, J.D. Reveille   +6 more
openaire   +1 more source

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study [PDF]

The Journal of Rheumatology, 2018
openaire   +2 more sources

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study. [PDF]

Inflamm Bowel Dis
Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS.   +13 more
europepmc   +1 more source

Tumor necrosis factor-alpha-mediated inflammatory bone loss: Pathogenic mechanisms and therapeutic potential of its inhibitors. [PDF]

Tzu Chi Med J
Lin WY, Pan YJ, Yeh KT, Su KY, Dharini KK, Chen IH, Wu WT, Lin MD, Peng CH.   +8 more
europepmc   +1 more source

Noninfectious uveitis: Management with biologic agents. [PDF]

Indian J Ophthalmol
Rathinam SR, Anjana S.
europepmc   +1 more source